Proxy adviser ISS slams Mylan’s Perrigo bid, flagging ‘unreasonable uncertainties’

Carly Helfand On Wednesday, a pair of proxy advisers recommended that Mylan shareholders support the company's quest to bag Irish target Perrigo. But not ISS. FiercePharma News

Lilly’s CEO keeps faith in the pipeline as biotech gets ‘too expensive’

Damian Garde Eli Lilly is staking its future on a pair of high-stakes Phase III programs, shying away from any big biotech buyouts as sticker prices continue to soar. FierceBiotech ...

FDA approves Purdue’s OxyContin for use in youth aged 11 to 16

Eric Palmer The addictive qualities of the powerful pain drug OxyContin have made it controversial, but the FDA has now approved it for youth 11 to 16 after asking maker Purdue Pharma ...

KemPharm spikes as its anti-abuse pain drug rolls toward the FDA

Damian Garde KemPharm, at work on an abuse-deterrent formulation of hydrocodone, said its lead drug performed well in a study designed to determine how easily the pill can be ground ...

Probing lawmakers grill Valeant on price hikes

Carly Helfand A pair of lawmakers is taking a look into recent drug price increases–and as part of the investigation, it wants some information from Valeant. FiercePharma News

Shire might dial up its $30B Baxalta offer, but not without more info

Alok Saboo Shire may consider upping its pitch for Baxalta, but first it needs more details on the financial future of its target. FierceBiotech News

Roche dumps its cancer drug R&D pact with Wilex

John Carroll Roche is bowing out of a two-year-old collaboration with a subsidiary of a struggling Wilex. FierceBiotech News

GSK says people and products were never in danger from Legionella bacteria in cooling towers

Eric Palmer GlaxoSmithKline says that the people and products at its manufacturing site in Zebulon, NC, were never in peril from the bacteria for Legionnaires' disease detected ...

State-level price caps? Massachusetts drug-cost pushback breaks new ground

Tracy Staton Massachusetts is joining the state-level push to tamp down drug prices. Lawmakers are proposing new disclosures about pharma's pricing decisions, just as they are in ...

Boehringer takes a neuroscience approach to obesity with latest deal

Damian Garde Boehringer Ingelheim is pairing up with a small California biotech to explore the role circuits in the nervous system play in obesity, scouting for drug targets that could ...

UPDATED: GSK site closed after Legionella bacteria detected in cooling tower

Eric Palmer After detecting the bacteria for Legionnaires' disease in its cooling tower, GlaxoSmithKline has temporarily closed a manufacturing plant in North Carolina and sent ...

Post-Sarepta, Art Krieg gets $20M to take a shot at an immuno-oncology Checkmate

John Carroll A year after getting bounced from a turbulent Sarepta, Art Krieg is prepping for his next act in biotech, snatching a failed lead immunology drug from the dying, Zurich-based ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS